HeartSciences Inc. (HSCS) - 10-Q Summary
Business Context and Reporting Period
Company: HeartSciences Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: July 31, 2026
Business Overview: A healthcare information technology company focused on advancing electrocardiography (ECG) through artificial intelligence (AI). The company's primary commercial focus is the MyoVista Insights platform, a cloud-native, device-agnostic ECG management system. The company has deprioritized the commercialization of its proprietary MyoVista wav ECG hardware device due to regulatory uncertainties and shifting market dynamics toward cloud-based solutions.
Key Financial Metrics
| Metric | Q2 2026 (Three Months Ended July 31) | Q2 2025 (Three Months Ended July 31) |
|---|---|---|
| Revenue | $2,100 | $1,900 |
| Net Loss | $(3,172,344) | $(2,054,994) |
| Loss Per Share (Basic & Diluted) | $(0.86) | $(1.58) |
| Cash and Cash Equivalents (End of Period) | $29,906 | $2,792,231 |
| Working Capital Deficit | $(4,821,203) | Not Provided |
| Accumulated Deficit | $(88,441,854) | $(78,182,629) |
| Total Debt (Current Portion) | $3,722,953 | Not Provided |
Note: Revenue is negligible and primarily derived from limited device sales outside the U.S. during the development phase.
Material Changes vs. Prior Period
- Liquidity Crisis: Cash and cash equivalents plummeted from $1.66 million at April 30, 2026, to $29,906 at July 31, 2026. Net cash used in operating activities was $1.32 million.
- Expense Surge: Selling, General, and Administrative (SG&A) expenses increased by 132% ($1.16 million) year-over-year, driven by approximately $0.5 million in professional/legal fees related to a proposed merger and $0.5 million in stock-based compensation.
- Inventory Write-Down: The company recorded a $251,880 reserve against inventory related to the MyoVista wav ECG device, reflecting a strategic shift away from hardware commercialization.
- Debt Restructuring: The $2.5M Streeterville Note was repaid in full via an exchange of accrued interest for common stock. A new $3.6M Streeterville Note remains outstanding with a maturity date of July 2027.
Guidance, Outlook, and Risks
- Going Concern: Management has raised substantial doubt regarding the company's ability to continue as a going concern. Current resources are deemed insufficient to fund operations for the next twelve months without additional financing.
- Proposed Merger: On June 23, 2026, the company entered into a Merger Agreement with Fortitude Mining Holdings, Inc. The transaction is subject to shareholder approval and other closing conditions. Failure to close would materially adversely affect the company.
- Nasdaq Compliance: The company received notice from Nasdaq on August 4, 2026, of non-compliance with Rule 5550(b)(1) due to stockholders' equity falling below the $2.5 million minimum. The company has 45 days to submit a compliance plan, which it intends to base on the proposed merger.
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting, including lack of proper approval processes and insufficient accounting resources.
- Regulatory Status: The MyoVista wav ECG device 510(k) submission remains under FDA review. The company is not currently committing significant resources to this device's commercialization.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.0 million private placement proceeds (closed August 12, 2026) and $1.2 million ATM proceeds (subsequent to quarter-end) to cover the $3.7 million in current debt obligations and operating burn rate.
- Merger Viability: Assess the likelihood of shareholder approval for the Fortitude Mining merger, which is the primary strategy to resolve the Nasdaq equity deficiency and liquidity crisis.
- Debt Covenants: Review the terms of the $3.6M Streeterville Note, specifically the redemption rights and the 5% penalty if the balance is not reduced by $1.25 million within 12 months.
- Internal Controls: Evaluate the remediation plan for the identified material weaknesses in financial reporting, which could impact future financial statement reliability.
- Revenue Trajectory: Confirm the status of the two commercial agreements signed in May 2026 for the MyoVista Insights platform and whether they have generated material revenue.